SHAREHOLDER ALERT: Berger Montague Reminds Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of Class Action Lawsuit Deadline

Group 1 - The core issue involves a securities fraud investigation against Spectrum Pharmaceuticals, initiated by Berger Montague on behalf of investors who acquired shares between March 17, 2022, and September 22, 2022 [1][2] - The class action lawsuit claims that Spectrum made false or misleading statements regarding its Pinnacle Study, which is a clinical trial for the drug poziotinib aimed at treating certain lung cancer patients [3] - Following a merger with Assertio Holdings, Spectrum's shares were delisted, raising concerns among investors [3] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representative in the class action [2] - Berger Montague has a long history in securities class action litigation, having represented investors for over five decades [5]